Skip to main content

Table 1 Baseline levels of total cholesterol (TC), HDL cholesterol (HDL), LDL cholesterol (LDL), TC/HDL ratio, triglycerides (TG) and Framingham score (FRS) across groups. Variable are expressed as means (±SD) or medians (Q1-Q3)

From: Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

Variable Switches from 2NRTI + EFV to Switches from 2NRTI + PI/r to
DTG EVG RPV DTG EVG RPV
TC (mg/dl) 198.5 (41.6) 207.4 (40.7) 196.5 (38.0) 209.9 (41.0) 203.7 (43.9) 189.2 (47.1)
HDL (mg/dl) 53.5 (16.7) 49.3 (14.4) 48.8 (13.8) 48.8 (14.7) 43.5 (12.3) 48.8 (21.0)
TC/HDL (mg/dl) 3.93 (1.1) 4.4 (1.1) 4.3 (1.4) 4.65 (1.6) 4.98 (1.6) 4.2 (1.3)
LDL (mg/dl) 117.0 (39.4) 128.2 (32.6) 120.3 (35.5) 126.0 (33.7) 123.5 (38.2) 111.1 (39.5)
TG (mg/dl) 114 (91.5–153.5) 126.5 (106–171) 109 (77–160) 142 (84–215) 150 (112–204) 117 (85–189)
FRS (%) 12.2 (6.7–25.3) 6.7 (3.9–9.4) 7.9 (4.7–13.2) 9.4 (4.5–21.6) 9.4 (4.5–15.6) 7.3 (3.3–13.2)
  1. NRTI nucleoside reverse transcriptase inhibitors, EFV efavirenz, PI/r ritonavir-boosted protease inhibitors, DTG dolutegravir, EVG elvitegravir, RPV rilpivirine